Raid Aljumaily is an Oncology physician. OpenAlex indexes 155 publications with 3,256 citations (h-index 22); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
600 Moye Blvd
Leo Jenkins Cancer Services, Ste. 3e127
Greenville, NC 278344300
Telephone
252-744-2315Registry record last updated 13 Aug 2014.
Clinical trials
- Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Sponsor: Alliance for Clinical Trials in Oncology
- Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
Sponsor: National Cancer Institute (NCI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20256 payments
- ARRAY BIOPHARMA INCProgram year20253 payments
- GENZYME CORPORATIONProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
22%Opioid Agonist14.4%Oxycodone Hcl51%Morphine Sulfate Er49%Part D<11 patientsPhenothiazine7.6%Prochlorperazine Maleate100%Part D≥33 patientsRespiratory
21.2%Opioid Agonist19.1%Hydrocodone-Acetaminophen100%Part D≥24 patientsbeta2-Adrenergic Agonist2.1%Albuterol Sulfate Hfa100%Part D<11 patientsMetabolism & gastrointestinal
18.3%Serotonin-3 Receptor Antagonist9.9%Ondansetron Hcl100%Part D≥33 patientsProton pump inhibitor4.7%Omeprazole100%Part D≥11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”